Drug Metabolizing Enzyme

Phase 1Small molecule

OOrsoBio, Inc

Drug Metabolizing Enzyme is one of 47 small molecule programs targeting Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

177 competitors in Obesity

#DrugCompanyPhaseTrials

Synthroid

IInstitut Jerome Lejeune

Phase 3

1 2

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 3

Maridebart Cafraglutide

Amgen

Phase 3

11 4

Retatrutide

Eli Lilly

Phase 3

6 5

Berobenatide

Pfizer

Phase 3

6 6

Mibavademab

Regeneron

Phase 3

1 7

Zenagamtide

Novo Nordisk

Phase 3

5 8

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 9

Survodutide

Boehringer Ingelheim

Phase 3

2 10

Actemra

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Obesity

NCT05822544

Clinical

Trials by Indication[1]

Obesity1 trial

A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food Effect and Potential Drug-Drug Interactions, and Preliminary Safety and Efficacy in Subjects With Obesity, With or Without Diabetes

Active, not recruiting·OOrsoBio, Inc·Phase 1·NCT05822544·564 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug Metabolizing Enzyme. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug Metabolizing Enzyme compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug Metabolizing Enzyme. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OrsoBio, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOrsoBio, Inc

Drug Metabolizing Enzyme

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Obesity1 trial

References

Drug Info

Quick Facts

Related News